Eli Lilly Buys 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 Billion, the Largest Psychedelic Deal Yet
Eli Lilly, the world’s largest pharmaceutical company, confirmed Thursday morning that it will acquire AtaiBeckley in a deal worth up to $3.8 billion. The purchase hands Lilly the company’s lead candidate, an intranasal form of 5-MeO-DMT for treatment resistant depression that is now entering Phase 3 trials.
No acquisition in psychedelic medicine has come close to this price. For anyone watching whether psychedelics would go mainstream, this is the clearest answer yet. Where this deal sits in the broader arms race is mapped in our overview of Big Pharma’s psychedelic drug race.
Do you work in the psychedelic industry? Save thousands on overhead and other fees (up to 40% on medical supplies, 20% on medmal and professional insurance, LegitScript certifications and more) by joining the first GPO for ketamine clinics and practitioners. There’s no cost to join and zero obligations. Sign up here!
Key Takeaways
| Key Takeaway | Detail |
|---|---|
| Buyer | Eli Lilly, world’s largest pharma company |
| Target | AtaiBeckley |
| Deal value | About $2.8 billion cash, up to $1 billion in milestone payments |
| Price per share | $6.75 cash, plus up to $2.50 in contingent payments |
| Lead candidate | BPL-003, intranasal 5-MeO-DMT for treatment resistant depression |
| Also included | VLS-01, a DMT based candidate |
| Premium | Roughly 25% over Wednesday’s closing price |
| Expected close | This quarter |
Inside the Deal Terms
Lilly will pay $6.75 per share in cash for all outstanding stock. Shareholders can earn up to $2.50 more per share if three milestones hit. The first pays $1.00 when VLS-01 reaches Phase 3 within four years. The second pays $0.50 if the FDA approves BPL-003 and the DEA reschedules it within five years. The third pays $1.00 if VLS-01 clears those same hurdles within seven years.
Those DEA rescheduling conditions matter. Both compounds remain Schedule I substances, and Lilly is betting billions that federal regulators will move them.
Big Pharma Keeps Buying In
The deal caps an 18 month buying spree. Otsuka acquired Transcend Therapeutics and its methylone candidate for PTSD earlier this year in a deal worth up to $1.225 billion. AbbVie paid up to $1.2 billion late last year for Gilgamesh’s bretisilocin, a candidate for major depressive disorder. Lilly just tripled the ceiling.
Not everyone is celebrating. Some AtaiBeckley investors told Psychedelic Alpha they wanted to stay invested through Phase 3 rather than cash out now. Others in the field question whether a pharmaceutical giant is the right steward for a compound as potent as 5-MeO-DMT. Lilly’s press release notably avoided the word psychedelic altogether, describing only the “rapid and durable reductions in depressive symptoms” seen in Phase 2b.
What This Means for Patients
The practical takeaway is speed. Lilly brings the money, regulatory muscle, and commercial reach to push BPL-003 through Phase 3 and into clinics faster than a small biotech could alone. Patients with treatment resistant depression already have ketamine and Spravato. If BPL-003 succeeds, a third rapid acting option could follow within a few years, backed by the same company that brought Zyprexa and Prozac era ambitions to psychiatry. The race is on, too. GH Research is developing an inhaled 5-MeO-DMT for the same condition, and it now competes with the deepest pockets in pharma.
RELATED: DMT Shows Promise as a Rapid Depression Treatment | What the FDA’s New Psychedelic Rulebook Means for Ketamine Clinics | Johnson & Johnson’s Spravato Surges Toward Blockbuster Status
